Jeremiah Moore, PharmD, BCOP

Many patients have baseline risk factors present at diagnosis because of older age and disease-related elements.

Two recent clinical trials highlight the novel therapy options available to patients in the upfront and relapsed settings.

This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.

Asciminib offers a new option for patients harboring the T315I mutation.

Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-based regimens.